Search
Jones Healthcare & Technology Innovation Conference: Wave CEO Paul Bolno discusses recent DMD data and regulatory feedback, and shares updates on alpha-1 antitrypsin, obesity, and Huntington's
He describes the 48 week data for the exon 53 DMD program, and discusses the company's plan to seek accelerated approval. Plus, guidance...
Apr 9
Jones Healthcare & Technology Innovation Conference: The CIO of XOMA Royalty describes the inner workings of the royalty business, and also how to help with biotech's negative enterprise problem
Brad Sitko describes how XOMA is able to do smaller deals than other larger investors in this space, and he gives examples of investments...
Apr 9
Jones Healthcare & Technology Innovation Conference: Trevi Therapeutics CEO Jennifer Good describes recent positive data in refractory chronic cough and previews upcoming IPF data
She describes how the mechanism of Haduvio differs from other programs in chronic cough, and covers the recent phase 2a RIVER data....
Apr 9
Jones Healthcare & Technology Innovation Conference: Jones Research analysts Catherine Novack and Debanjana Chatterjee share their take on biotech and comment on companies they cover
They discusses the macro and regulatory factors that have affected the sector so strongly, and comment on Wave, Korro, ProQr, Capricor,...
Apr 9
Biotech CEO Sisterhood: X4 Pharmaceuticals' CEO Paula Ragan on her career and running a commercial stage company in the rare disease space
Interviewed by Sisterhood editorial board member Erika Smith, Paula Ragan shares her career path and things she has learned along the...
Apr 8
Checking in on the progress of Trinity by Breakthrough in Oxford, UK
After its recent topping off ceremony, BiotechTV's Amy Brown checked in on the construction progress of Trinity by Breakthrough...
Apr 8
Elias Zerhouni and Andy Plump discuss the future of multispecific biologics
Interviewed by Andy Plump, President of R&D at Takeda, Dr. Zerhouni discusses the rationale for multispecifics and the science behind...
Apr 7
BioVenture VoiCes Episode 16: RA Capital's Josh Resnick
Josh Resnick describes his career path, which includes working on the venture side of both private funds and pharma (Merck). He explains...
Apr 7
HSBC Innovation Banking: Q1 2025 Venture Numbers for Healthcare
HSBC's Jonathan Norris shares an update on Q1 venture numbers for healthcare, and how the venture side of the sector is holding up in...
Apr 4
Analyst Thursdays: Stifel's Alex Thompson updates us on the latest news and upcoming catalysts in the I&I space
He shares his take on biotech and discusses argenx, Immunovant, AnaptysBio, Apogee, Dianthus, and Viridian.
Apr 3
Anglo Nordic Life Science Conference: The CEO of Cure Parkinson's talks about their work, and participating in the International Linked Clinical Trials Initiative
CEO Helen Matthews describes the types of medicines they are supporting for clinical trials (including Ambroxol and GLP-1s), and folding...
Apr 3
Anglo Nordic Life Science Conference: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants
Co-Founder and CEO Thomas Kledal describes the science behind this platform and program. Plus, how having access to donated kidneys is...
Apr 3
On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress
CEO Jason Gardner describes Ampersand's platform that is designed to make medicines act at the site of disease. He also shares updates on...
Apr 3
BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round
CEO Nicki Thompson describes why she believes the company is differentied in the field, and how TRIMTECH's construct is designed to...
Apr 2
Vida Ventures named Matt Cohen and Brian Goodman new Managing Directors today. BiotechTV caught up with Brian in Vida's Boston office
He describes his background in life sciences investing and shares his take on the current state of the sector.
Apr 2
After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection
He describes why a 'one-size-fits-all' approach has caused numerous ophthalmology trials to fail in the past, and why Character believes...
Apr 1
Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech
They discuss the difference between how biotech companies operate from large pharmas, including how history shows some new biotech...
Apr 1
BioTrinity 2025: AlveoGene Executive Chair David Hipkiss describes the company's unique inhaled gene therapy platform that fuses a Sendai virus and Lentivirus, and can be redosed
He describes the science behind the platform, which is already being used by Boehringer Ingelheim for cystic fibrosis. AlveoGene has...
Apr 1
Miami based Galatea Bio raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry
Founder and CEO Carlos Bustamante tells BiotechTV's AI Correspondent, Ryan Flinn, about the biobank and why it is important to better...
Mar 27
Biotech CEO Sisterhood: Gallop Oncology CEO Luba Greenwood on the importance of the Sisterhood, the Massachusetts life sciences ecosystem, and Gallop's work
Interviewed by Normunity CEO Rachel Humphrey at MassBio's 2025 State of Possible Conference, Luba explains how the Sisterhood arms...
Mar 27
.png){kind=logo}
